Sanofi is a French multinational pharmaceutical and healthcare company headquartered in Paris. The company was established in 1973 and now trades on Euronext Paris and Nasdaq.
IDT's study showed UNCOVERseq achieved 97.6% sensitivity and 78% precision for CRISPR off-target nomination. Scribe will present new data at ASGCT and EAS, including STX-1150. Watchmaker licensed CRISPR-Cas9 IP for NGS normalization.
Novartis marks 30 years since its 1996 merger, citing advances in targeted therapy, cell therapy, gene therapy, and malaria. It also named a Levant Country President and won two clinical research awards in Saudi Arabia.
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
AI drug discovery is moving from hype to proof in 2026, with multi-billion-dollar partnerships, new joint initiatives, and major investments accelerating AI-native biotech pipelines and data-driven deals.
Trump’s phased tariffs on medicines spur over $400 billion in US pharma investments. Indian generic makers face a 2028 deadline to adapt.
A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
Bristol Myers Squibb, Sanofi, and Pfizer have filed new patent infringement suits over drugs including Camzyos, Lantus, and abrocitinib, while the Federal Circuit denied Sarepta's rehearing bid in a Regenxbio DNA patent case.
The FDA approved Tzield for stage 3 type 1 diabetes, and the therapy was given to children in Canada for the first time. Research also advanced on engineered islets and stem-cell treatments.
Arbutus and Genevant filed three new lawsuits against Pfizer and BioNTech over mRNA vaccine lipid nanoparticle patents, shortly after receiving a $178 million payment from Moderna. Sanofi also launched two separate patent suits against Pfizer and Moderna. A Delaware court previously narrowed Moderna's defenses in a related case.
Anthropic launched Claude Science, an AI workbench with 60+ skills and databases, and began preclinical programs for neglected diseases. A demo analyzed 100 rare genetic diseases in under an hour.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779408 |
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above. |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07771439 |
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07735767 |
Tdap Vaccination During Pregnancy or Postpartum and Lactation-Related Outcomes |
COMPLETED | |
| NCT07734753 |
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events |
ACTIVE_NOT_RECRUITING | |
| NCT07734649 |
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older |
RECRUITING | PHASE1/PHASE2 |
| NCT07726914 |
Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07721649 |
Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP) |
NOT_YET_RECRUITING | NA |
| NCT07714512 |
Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia |
RECRUITING | PHASE1/PHASE2 |
| NCT07710872 |
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China |
NOT_YET_RECRUITING | PHASE3 |
| NCT07704580 |
Phase 1b/2 Study of IV Sarilumab in Adult With RA |
RECRUITING | PHASE1/PHASE2 |
